Then treatment response in terms of chemotherapy and TKI target therapy was further evaluated using public data, while the impact of SETD2 downregulation on chemotherapy response was further investigated by IC50 scores of Cisplatin on melanoma A375 cell lines cultured with SETD2 inhibitor or knocked out SETD2. The gene discussed is SETD2; the disease is melanoma.